Evotec and Dewpoint Therapeutics enter strategic partnership in oncology
Agreement is based on a risk-sharing arrangement followed by milestone and royalty payments to Evotec based on success of overall programmes
Evotec SE and Dewpoint therapeutics announced a strategic R&D collaboration to advance Dewpoint’s leading oncology pipeline programmes of condensate modifying therapeutics (“c-mods”) to Investigational New Drug Applications (“INDs”) using Evotec’s industry-leading fully integrated data-driven platform (“INDiGO”).
The partnership brings together Dewpoint’s advanced oncology pipeline programmes discovered using its groundbreaking condensate biology and A.I. technology platform for identifying modulators of biomolecular condensates with Evotec’s leading capabilities to de-risk and accelerate pre-clinical development candidates (“PDCs”) to first-in-human (“FIH”) clinical studies.
Under the collaboration, Evotec will facilitate the rapid development of Dewpoint’s oncology assets using Evotec’s fully integrated clinical-enabling INDiGO platform to de-risk and accelerate the path to clinical testing. The partnership also enables Dewpoint to maximise capital efficiency while reducing risk. The agreement is based on a risk-sharing arrangement followed by milestone and royalty payments to Evotec based on the success of the overall programmes.
Dr Matthias Evers, Chief Business Officer of Evotec, commented: “We are excited to enter this strategic development partnership with Dewpoint. Their innovative approach is based on a holistic understanding, which can significantly expand the target space across indications. By combining our complementary expertise, Evotec’s development platform will serve as the capital-efficient IND engine for this highly collaborative partnership. We look forward to working closely together with their team to make Dewpoint’s groundbreaking innovations available to patients.”
“Dewpoint’s strategic partnership with Evotec leverages the world-class speed of their development platform to accelerate our oncology assets into the clinic. Evotec’s integrated state-of-the-art operational technologies have been proven to deliver high quality INDs across the industry. A strategic relationship of this nature significantly enhances our development capabilities which can be transformative for a company at our stage of development, and we are delighted to have been able to forge this partnership with a leader like Evotec,” commented Ameet Nathwani, M.D., CEO at Dewpoint.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
